|
Malignant neoplasm of breast
|
0.320 |
Biomarker
|
disease |
BEFREE |
ALG-2 also promotes breast cancer cell proliferation, survival, and motility in vitro.
|
27926525 |
2017 |
|
Malignant neoplasm of breast
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these data suggest that miR-124-3p inhibits tumor metastasis by inhibiting PDCD6 expression, and that the miR-124-3p/PDCD6 signaling axis may be a potential target for novel treatments in patients with advanced BC.
|
29387242 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Deregulated ALG-2/HEBP2 axis alters microtubule dynamics and mitotic spindle behavior to stimulate cancer development.
|
28004381 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrate that the expression of ALG-2 is significantly upregulated in breast cancer tissues and is correlated with clinicopathological characteristics indicative of tumor malignancy.
|
27926525 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Interestingly, miR-183 may function as an oncogene and may enhance cell proliferation by targeting PDCD6, implying a potential therapeutic target for this malignancy.
|
27738758 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Both PDCD6 and cisplatin respectively inhibited cancer cell proliferation in a dose-dependent manner.
|
22142513 |
2012 |
|
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70-0.96, <i>p</i> = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, <i>p</i> < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, <i>p</i> = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, <i>p</i> = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67-0.86, <i>p</i> < 0.00001, G vs T) genetic model.
|
29872511 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in survival pathways in cancer.
|
22369209 |
2012 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The calcium binding protein ALG-2 is upregulated in several types of cancerous tissues and cancer cell death may be a consequence of ALG-2 downregulation.
|
30240438 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The calcium binding protein ALG-2 is upregulated in several types of cancerous tissues and cancer cell death may be a consequence of ALG-2 downregulation.
|
30240438 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Both PDCD6 and cisplatin respectively inhibited cancer cell proliferation in a dose-dependent manner.
|
22142513 |
2012 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Programmed cell death 6 (PDCD6) beside its known proapoptotic functions may be a player in survival pathways in cancer.
|
22369209 |
2012 |
|
Primary malignant neoplasm
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrate that the expression of ALG-2 is significantly upregulated in breast cancer tissues and is correlated with clinicopathological characteristics indicative of tumor malignancy.
|
27926525 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Deregulated ALG-2/HEBP2 axis alters microtubule dynamics and mitotic spindle behavior to stimulate cancer development.
|
28004381 |
2017 |
|
Primary malignant neoplasm
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Overall, our results indicate that PDCD6 rs3756712 T>G polymorphism was significantly associated with decreased risk of cancer under codominant (OR = 0.82, 95%CI = 0.70-0.96, <i>p</i> = 0.01, TG vs TT; OR = 0.53, 95%CI = 0.39-0.72, <i>p</i> < 0.0001, GG vs TT), dominant (OR = 0.76, 95%CI = 0.66-0.89, <i>p</i> = 0.0004, TG+GG vs TT), recessive (OR = 0.57, 95%CI = 0.43-0.78, <i>p</i> = 0.0003, GG vs TT+TG), and allele (OR = 0.76, 95%CI = 0.67-0.86, <i>p</i> < 0.00001, G vs T) genetic model.
|
29872511 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Interestingly, miR-183 may function as an oncogene and may enhance cell proliferation by targeting PDCD6, implying a potential therapeutic target for this malignancy.
|
27738758 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
No correlation was found between ALG-2 staining intensity and survival of patients with lung, breast or colon cancer. siRNA mediated ALG-2 downregulation led to a significant reduction in viability of HeLa cells indicating that ALG-2 may contribute to tumor development and expansion.
|
19383317 |
2008 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
PDCD6, the encoding gene for programmed cell death protein 6, may function as a tumor suppressor gene.
|
23167403 |
2012 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Patients with medium or high levels of PDCD6 mRNA were at higher risk for disease progression, compared to those with low levels (HR, 1.29; P = 0.024 for medium levels; and HR, 1.57; P = 0.045 for high levels) after adjusting for age, disease stage, tumor grade, histologic type and residual tumor size.
|
22369209 |
2012 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The aim of the present study was to investigate whether ALG-2 plays a crucial role in tumor cell proliferation, migration and tumorigenicity.
|
28300556 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Here, we demonstrate that the expression of ALG-2 is significantly upregulated in breast cancer tissues and is correlated with clinicopathological characteristics indicative of tumor malignancy.
|
27926525 |
2017 |
|
Malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Our data show that the gene copy numbers and mRNA levels for both ALG-2 and HEBP2 are significantly upregulated in breast and lung cancer.
|
28004381 |
2017 |
|
Malignant neoplasm of lung
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, the GG genotype at PDCD6 rs4957014 significantly decreased the risk of lung cancer among males (adjusted OR =0.29, 95% CI =0.14-0.57) and smokers (adjusted OR =0.34, 95% CI =0.18-0.61) but not among females and non-smokers.
|
31496727 |
2019 |
|
Malignant neoplasm of lung
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in PDCD6 and susceptibility to lung cancer.
|
23167403 |
2012 |
|
Carcinoma of lung
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, the GG genotype at PDCD6 rs4957014 significantly decreased the risk of lung cancer among males (adjusted OR =0.29, 95% CI =0.14-0.57) and smokers (adjusted OR =0.34, 95% CI =0.18-0.61) but not among females and non-smokers.
|
31496727 |
2019 |